Related Experiment Videos
The major outer membrane protein of a single Chlamydia trachomatis serovar can possess more than one serovar-specific
1Department of Medicine, Indiana University of Medicine, Indianapolis, USA.
Abstract:
The major outer membrane proteins (MOMPs) of human Chlamydia trachomatis serovars exhibit four regions of variable amino acid sequences (VS1 to VS4) harboring serovar-specific B-cell epitopes. Antibody responses to these epitopes may contribute to acquired protection against human chlamydial infection. MOMP B-cell epitopes defined by 22 different serovar-specific or bispecific murine monoclonal antibodies were localized with synthetic peptides representing the four VS regions of seven genital serovars (D, Da, E, F, G, H, and K). Serovar F possessed two distinct serovar-specific epitopes, located in VS2 and VS4, while serovar K possessed three distinct serovar-specific epitopes, located in VS1, VS2, and VS4. Serovar D- and serovar Da-specific epitopes were located in VS1. Regardless of whether the serovar was from the B (serovars D, Da, and E), C (serovars H and K), or F-G (serovars F and G) serogroup, all serovar-specific epitopes were found in three discrete subgroups of MOMPs. These subregions comprised all central portion of VS1, residues 70 to 77; the amino-terminal half of VS2, residues 139 to 149; and the carboxyl-terminal third of VS4, residues 305 to 315. Monoclonal antibodies to each of these subregions neutralized infectivity in standard HaK cell culture assays. These findings are relevant to the development of an MOMP or MOMP subunit vaccine.
Insights
Antibodies targeting specific regions of Chlamydia trachomatis major outer membrane proteins (MOMPs) can neutralize infection. Identifying these serovar-specific epitopes is key for developing effective MOMP-based vaccines.
Area of Science:
- Microbiology
- Immunology
- Vaccine Development
Background:
- Human Chlamydia trachomatis serovars have major outer membrane proteins (MOMPs) with variable regions (VS1-VS4).
- These variable regions contain serovar-specific B-cell epitopes, which may be targets for protective antibodies.
- Understanding these epitopes is crucial for developing Chlamydia vaccines.
Purpose of the Study:
- To map the locations of serovar-specific B-cell epitopes on Chlamydia trachomatis MOMPs.
- To investigate the potential of these epitopes as targets for neutralizing antibodies.
- To inform the development of MOMP-based vaccines against Chlamydia trachomatis.
Main Methods:
- Localization of MOMP B-cell epitopes using synthetic peptides from variable regions (VS1-VS4) of seven genital serovars.
- Characterization of epitopes using 22 serovar-specific or bispecific murine monoclonal antibodies.
- Assessment of infectivity neutralization by monoclonal antibodies in HaK cell culture assays.
Main Results:
- Serovar F had epitopes in VS2 and VS4; Serovar K had epitopes in VS1, VS2, and VS4.
- Serovar D and Da specific epitopes were located in VS1.
- All serovar-specific epitopes clustered in three conserved subregions of MOMPs: central VS1 (residues 70-77), amino-terminal VS2 (residues 139-149), and carboxyl-terminal VS4 (residues 305-315).
Conclusions:
- Identified conserved subregions within MOMP variable regions harbor critical serovar-specific epitopes.
- Monoclonal antibodies targeting these subregions demonstrated infectivity neutralization.
- These findings support the development of MOMP or MOMP subunit vaccines for Chlamydia trachomatis prevention.